Результати пошуку - Emilio Alba

Уточнити результати
  1. 1
    Playing only one instrument may be not enough: Limitations and future of the antiangiogenic treatment of cancer

    Playing only one instrument may be not enough: Limitations and future of the antiangiogenic treatment of cancer за авторством Ana R. Quesada, Miguel Ángel Medina, Emilio Alba

    Опубліковано 2007
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer

    The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer за авторством Nuria Ribelles, Ángela Santonja, Bella Pajares, Casilda Llácer, Emilio Alba

    Опубліковано 2013
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  3. 3
    Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study

    Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study за авторством Antonio Rueda‐Domínguez, A. Márquez, Josep Gumà, Marta Llanos, J. Herrero, M Nieves, José Miramón, Emilio Alba

    Опубліковано 2004
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review

    Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review за авторством Jesús García‐Foncillas, Emilio Alba, Enrique Aranda, Eduardo Díaz‐Rubio, Rafael López‐López, Josep Tabernero, Ana Vivancos

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  5. 5
    Bevacizumab–Capecitabine (BEV–CAP) After Initial 1st-Line Bevacizumab–Docetaxel (BEV–DOC) in Patients (PTS) With HER2-Negative Metastatic Breast Cancer (MBC): Safety Analysis of the IMELDA Trial

    Bevacizumab–Capecitabine (BEV–CAP) After Initial 1st-Line Bevacizumab–Docetaxel (BEV–DOC) in Patients (PTS) With HER2-Negative Metastatic Breast Cancer (MBC): Safety Analysis of th... за авторством Joseph Gligorov, Emilio Alba-Conejo, José Bines, P. Cortes, Dinesh Doval, Zefei Jiang, Ulrich Freudensprung, Giorgio Mustacchi

    Опубліковано 2012
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications

    Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications за авторством Ana Godoy-Ortiz, Alfonso Sánchez‐Muñoz, M Rosario Chica Parrado, Martina Álvarez, Nuria Ribelles, Antonio Rueda‐Domínguez, Emilio Alba

    Опубліковано 2019
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  7. 7
    Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response

    Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response за авторством Qingyang Xiao, André Nobre, Pilar Piñeiro, Miguel‐Ángel Berciano‐Guerrero, Emilio Alba, Manuel Cobo, Volker M. Lauschke, Isabel Barragán

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  8. 8
    Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

    Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer за авторством Alfonso Sánchez‐Muñoz, Elena Gallego, Vanessa de Luque, Luis Gustavo Perez‐Rivas, Luís Vicioso, Nuria Ribelles, José Lozano, Emilio Alba

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    Efficacy and Safety of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) After Initial First-Line Bev Plus Docetaxel (Doc) for Her2-Negative Metastatic Breast Cancer (Mbc): Imelda Randomised Phase III Trial

    Efficacy and Safety of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) After Initial First-Line Bev Plus Docetaxel (Doc) for Her2-Negative Metastatic Breast Cancer... за авторством Joseph Gligorov, D.C. Doval, José Bines, Z. Jiang, Emilio Alba, P. Cortes, Stefanie Srock, Sabine de Ducla, Ulrich Freudensprung, Giorgio Mustacchi

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients

    GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients за авторством Victoria Contreras-Bolívar, Francisco José Sánchez-Torralvo, María Dolores Martínez Ruíz, Inmaculada González-Almendros, Manuel Barrios, Susana Padín, Emilio Alba, Gabriel Olveira

    Опубліковано 2019
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    Challenges and achievements of liquid biopsy technologies employed in early breast cancer

    Challenges and achievements of liquid biopsy technologies employed in early breast cancer за авторством Alfonso Alba-Bernal, Rocío Lavado-Valenzuela, María Emilia Domínguez-Recio, Begoña Jiménez-Rodríguez, María Isabel Queipo‐Ortuño, Emilio Alba, Iñaki Comino‐Méndez

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  12. 12
    Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study

    Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast... за авторством Emilio Alba, Miguel Martín, Manuel Ramos, Encarna Adrover, A. Balil, Carlos Jara, Agustí Barnadas, António Fernández, Pedro Sánchez‐Rovira, Margarita Amenedo, Antonio Casado

    Опубліковано 2004
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2

    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic... за авторством Sunil Verma, Joyce O’Shaughnessy, Howard A. Burris, Mario Campone, Emilio Alba, David Chandiwana, Anand A. Dalal, Santosh Sutradhar, Mauricio Monaco, Wolfgang Janni

    Опубліковано 2018
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment

    Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment за авторством Aurora Laborda-Illanes, Lidia Sánchez‐Alcoholado, María Emilia Domínguez-Recio, Begoña Jiménez-Rodríguez, Rocío Lavado-Valenzuela, Iñaki Comino‐Méndez, Emilio Alba, María Isabel Queipo‐Ortuño

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  15. 15
    A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression

    A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression за авторством Nuria Ribelles, J. Lopez-Siles, A. Bartolomé Sánchez, Emilio Esteban, María‐José Sánchez, F. Carabantes, P. Sanchez-Rovira, A. Márquez, Rosario Dueñas, Isabel Sevilla, Emilio Alba

    Опубліковано 2008
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    A microRNA Signature Associated with Early Recurrence in Breast Cancer

    A microRNA Signature Associated with Early Recurrence in Breast Cancer за авторством Luis Gustavo Perez‐Rivas, José M. Jerez, Rosario Carmona, Vanessa de Luque, Luís Vicioso, M. Gonzalo Claros, Enrique Viguera, Bella Pajares, Alfonso Sánchez, Nuria Ribelles, Emilio Alba, José Lozano

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

    Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines за авторством Denis Talbot, Vladimir Moiseyenko, Simon Van Belle, S.M. O'Reilly, Emilio Alba, Stephen P. Ackland, Peter D. Eisenberg, David Melnychuk, Tadeusz Pieńkowski, H-U Burger, Siobhan Laws, B Osterwalder

    Опубліковано 2002
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer: the EarLEE adjuvant clinical trials program

    The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer: the EarLEE adjuvant clinical trials progra... за авторством Michelino De Laurentiis, Filippo Montemurro, Thomas Bachelot, Miguel Martín, C.H. Barrios, Bella Kaufman, Peter Schmid, Emilio Alba, Véronique Dièras, S. Mondal, A. Chakravartty, Mark Shilkrut, Michelle C. Miller, Michael Untch

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer

    Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer за авторством Iñaki Comino‐Méndez, Jesús Velasco-Suelto, Javier Pascual, Esperanza López-López, María Elena Quirós-Ortega, Celia Gaona-Romero, Alejandro Martín-Muñoz, Patricia Losana, Yanira Heredia, Emilio Alba, Ángel Guerrero‐Zotano

    Опубліковано 2025
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study

    Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study за авторством Nuria Ribelles, Javier Pascual, Laura Gálvez, Sofía Ruiz-Medina, Javier Garcia-Corbacho, José Carlos Benítez, María Emilia Domínguez-Recio, Esperanza Torres, L. Martinez Oliva, Manuel Zalabardo-Aguilar, Antonio Rueda, Emilio Alba

    Опубліковано 2024
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: